10 Obesity Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Obesity Studies in Tucson

NCT07351045Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multi...

Tucson, AZPHASE32,000 participantsHoffmann-La Roche

View Study Details

NCT07351058Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multi...

Tucson, AZPHASE31,600 participantsHoffmann-La Roche

View Study Details

NCT06143956Recruiting

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight ma...

Tucson, AZPHASE21,481 participantsEli Lilly and Company

View Study Details

NCT07282600Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Pa...

Tucson, AZPHASE31,035 participantsEli Lilly and Company

View Study Details

NCT07392190Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and ...

Tucson, AZPHASE3900 participantsEli Lilly and Company

View Study Details

NCT07575932Recruiting

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that h...

Tucson, AZPHASE2872 participantsPfizer

View Study Details

NCT07589608Recruiting

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with ...

Tucson, AZPHASE2400 participantsEli Lilly and Company

View Study Details

NCT07215559Recruiting

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Parti...

Tucson, AZPHASE2200 participantsEli Lilly and Company

View Study Details

NCT07441252Recruiting

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or ov...

Tucson, AZPHASE2180 participantsAmgen

View Study Details

NCT07656727Recruiting

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may impr...

Tucson, AZPHASE2160 participantsBioAge Labs, Inc.

View Study Details

About Obesity Clinical Trials in Tucson

Obesity is a complex chronic disease involving an excessive amount of body fat that increases the risk of other diseases and health problems. It affects over 650 million adults worldwide. Treatment approaches include lifestyle modifications, medications (GLP-1 agonists), and bariatric surgery.

There are currently 10 obesity clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 8,828 participants. Research is being sponsored by Hoffmann-La Roche, Eli Lilly and Company, Pfizer and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Obesity Clinical Trials in Tucson — FAQ

Are there obesity clinical trials in Tucson?

Yes, there are 10 obesity clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What obesity treatments are being tested?

The 10 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for obesity.

Data updated July 18, 2026 from ClinicalTrials.gov